These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 20478956)

  • 1. New predictors of adverse cardiovascular events following vascular surgery.
    van Lammeren GW; de Vries JP; Vink A; de Kleijn DP; Moll FL; Pasterkamp G
    Semin Cardiothorac Vasc Anesth; 2010 Jun; 14(2):148-53. PubMed ID: 20478956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biobanks and the search for predictive biomarkers of local and systemic outcome in atherosclerotic disease.
    Hurks R; Peeters W; Derksen WJ; Hellings WE; Hoefer IE; Moll FL; de Kleijn DP; Pasterkamp G
    Thromb Haemost; 2009 Jan; 101(1):48-54. PubMed ID: 19132188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local atherosclerotic plaques are a source of prognostic biomarkers for adverse cardiovascular events.
    de Kleijn DP; Moll FL; Hellings WE; Ozsarlak-Sozer G; de Bruin P; Doevendans PA; Vink A; Catanzariti LM; Schoneveld AH; Algra A; Daemen MJ; Biessen EA; de Jager W; Zhang H; de Vries JP; Falk E; Lim SK; van der Spek PJ; Sze SK; Pasterkamp G
    Arterioscler Thromb Vasc Biol; 2010 Mar; 30(3):612-9. PubMed ID: 20018935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From vulnerable plaque to vulnerable patient: the search for biomarkers of plaque destabilization.
    Hellings WE; Peeters W; Moll FL; Pasterkamp G
    Trends Cardiovasc Med; 2007 Jul; 17(5):162-71. PubMed ID: 17574124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Composition of carotid atherosclerotic plaque is associated with cardiovascular outcome: a prognostic study.
    Hellings WE; Peeters W; Moll FL; Piers SR; van Setten J; Van der Spek PJ; de Vries JP; Seldenrijk KA; De Bruin PC; Vink A; Velema E; de Kleijn DP; Pasterkamp G
    Circulation; 2010 May; 121(17):1941-50. PubMed ID: 20404256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipoprotein-associated phospholipase A2: role in atherosclerosis and utility as a cardiovascular biomarker.
    Toth PP; McCullough PA; Wegner MS; Colley KJ
    Expert Rev Cardiovasc Ther; 2010 Mar; 8(3):425-38. PubMed ID: 20222820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk assessment in the patient with established peripheral arterial disease.
    Haugen S; Casserly IP; Regensteiner JG; Hiatt WR
    Vasc Med; 2007 Nov; 12(4):343-50. PubMed ID: 18048472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does the preventive effect of different drugs depend on location of the atherosclerotic process?
    Poredos P; Jezovnik MK
    Int Angiol; 2008 Aug; 27(4):274-80. PubMed ID: 18677288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Psychosocial factors as predictors of atherosclerosis and cardiovascular events: contribution from animal models].
    Alboni P; Alboni M
    G Ital Cardiol (Rome); 2006 Nov; 7(11):747-53. PubMed ID: 17216916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemokines and cardiovascular risk.
    Aukrust P; Halvorsen B; Yndestad A; Ueland T; Øie E; Otterdal K; Gullestad L; Damås JK
    Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):1909-19. PubMed ID: 18669888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From vulnerable plaque to vulnerable patient--Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report.
    Naghavi M; Falk E; Hecht HS; Jamieson MJ; Kaul S; Berman D; Fayad Z; Budoff MJ; Rumberger J; Naqvi TZ; Shaw LJ; Faergeman O; Cohn J; Bahr R; Koenig W; Demirovic J; Arking D; Herrera VL; Badimon J; Goldstein JA; Rudy Y; Airaksinen J; Schwartz RS; Riley WA; Mendes RA; Douglas P; Shah PK;
    Am J Cardiol; 2006 Jul; 98(2A):2H-15H. PubMed ID: 16843744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale, design, methods and baseline characteristics of the Asklepios Study.
    Rietzschel ER; De Buyzere ML; Bekaert S; Segers P; De Bacquer D; Cooman L; Van Damme P; Cassiman P; Langlois M; van Oostveldt P; Verdonck P; De Backer G; Gillebert TC;
    Eur J Cardiovasc Prev Rehabil; 2007 Apr; 14(2):179-91. PubMed ID: 17446795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [What are the biomarkers of atherosclerosis and cardiovascular risk?].
    Riesen WF
    Rev Med Suisse; 2008 Mar; 4(148):636-8, 640-3. PubMed ID: 18459658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyvascular atherosclerotic disease: recognizing the risks and managing the syndrome.
    Yakubov S
    Curr Med Res Opin; 2009 Nov; 25(11):2631-41. PubMed ID: 19769467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemokines in cardiovascular risk prediction.
    Aukrust P; Yndestad A; Smith C; Ueland T; Gullestad L; Damås JK
    Thromb Haemost; 2007 May; 97(5):748-54. PubMed ID: 17479185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of site and extent of clinically evident cardiovascular disease and atherosclerotic burden on new cardiovascular events in patients with Type 2 diabetes. The SMART study.
    Gorter PM; Visseren FL; Algra A; van der Graaf Y;
    Diabet Med; 2007 Dec; 24(12):1352-60. PubMed ID: 18042079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-reactive protein: risk assessment in the primary prevention of atherosclerotic disease. Has the time come for including it in the risk profile?
    Koenig W
    Ital Heart J; 2001 Mar; 2(3):157-63. PubMed ID: 11305526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal risk factor modification and medical management of the patient with peripheral arterial disease.
    Chi YW; Jaff MR
    Catheter Cardiovasc Interv; 2008 Mar; 71(4):475-89. PubMed ID: 18307227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechano-pathobiology of atherogenesis: a review.
    Vanepps JS; Vorp DA
    J Surg Res; 2007 Sep; 142(1):202-17. PubMed ID: 17612564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of calcium antagonists on atherosclerosis progression and intima media thickness].
    Zannad F
    Drugs; 2000; 59 Spec No 2():39-46. PubMed ID: 11002857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.